ACTINOGEN MEDICAL LIMITED news, videos and press releases
For more news please use our advanced search feature.
ACTINOGEN MEDICAL LIMITED - More news...
ACTINOGEN MEDICAL LIMITED - More news...
-
Actinogen Medical – equity proposition
- Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
- Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem
-
Actinogen Medical – executive interview
- Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial
- Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
- Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
- Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
- Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
- First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
- Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
- Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
- Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
- Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update
- Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention
- Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference
- FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial
- Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
-
Actinogen Medical - executive interview
- Actinogen Medical (AGW): re-initation — Cognitive enhancer targeting key diseases
- Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients
-
Executive interview – Actinogen Medical
- Cognitive Improvement Demonstrated With Xanamem™: Actinogen Medical
-
Executive interview – Actinogen Medical
- Edison initiates coverage on Actinogen Medical (ACW)
